Novamab is a clinical-stage biotech company dedicated to creating life-changing therapies for patients through innovative VHH technology. We take pride in our highly differentiated and innovative product pipeline, which targets high-potential markets such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).

Our most advanced project, an inhaled IL-4Rα VHH, has progressed to Phase II clinical trials, while our inhaled TSLP VHH is preparing to enter Phase IB proof-of-concept studies. Additionally, we are actively developing several bispecific and oral VHH antibody products aimed at treating inflammatory bowel disease (IBD).